The Application of Static Magnetic Stimulation Reduces Survival of SH-SY5Y Neuroblastoma Cells.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 14 12 2022
revised: 30 01 2023
accepted: 01 02 2023
medline: 29 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: ppublish

Résumé

Central nervous system cancer is still a major public health issue. The effectiveness of treatments is limited and varies depending on the severity of disease. Therefore, there is a demand for the development of novel therapies. Static magnetic stimulation (SMS) emerges as a new therapeutic option. The aim of this study was to evaluate the SMS effects on neuroblastoma cells in culture. SH-SY5Y neuroblastoma cells were exposed to 0.3T SMS for 6, 12, 24, 36, 72 h, and 6 days. Cell viability (MTT), cell death (annexin-V/PI staining) and cell cycle (DNA content), cell proliferation (CFSE), autophagy (acridine orange), and total mitochondrial mass (MitoTracker™ Red) were analyzed to establish the cellular response to SMS. The viability of SH-SY5Y cells was reduced after exposure to SMS for 24 h and 6 days (p<0.05), without differences for the other times (p>0.05); however, this effect was not related to cell death or cell cycle arrest (p>0.05). In contrast, the viability of human malignant melanoma (HMV-II) cells, used as a tumoral control, was not affected. In addition, stimulated SH-SY5Y cells presented a decrease in mitochondrial mass at both exposure times and a reduction in autophagy and cell proliferation after 6 days (p<0.05). SMS application appears to be a promising adjuvant therapy for the treatment of neuroblastoma since it decreases the survival of SH-SY5Y neuroblastoma cells.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Central nervous system cancer is still a major public health issue. The effectiveness of treatments is limited and varies depending on the severity of disease. Therefore, there is a demand for the development of novel therapies. Static magnetic stimulation (SMS) emerges as a new therapeutic option. The aim of this study was to evaluate the SMS effects on neuroblastoma cells in culture.
MATERIALS AND METHODS METHODS
SH-SY5Y neuroblastoma cells were exposed to 0.3T SMS for 6, 12, 24, 36, 72 h, and 6 days. Cell viability (MTT), cell death (annexin-V/PI staining) and cell cycle (DNA content), cell proliferation (CFSE), autophagy (acridine orange), and total mitochondrial mass (MitoTracker™ Red) were analyzed to establish the cellular response to SMS.
RESULTS RESULTS
The viability of SH-SY5Y cells was reduced after exposure to SMS for 24 h and 6 days (p<0.05), without differences for the other times (p>0.05); however, this effect was not related to cell death or cell cycle arrest (p>0.05). In contrast, the viability of human malignant melanoma (HMV-II) cells, used as a tumoral control, was not affected. In addition, stimulated SH-SY5Y cells presented a decrease in mitochondrial mass at both exposure times and a reduction in autophagy and cell proliferation after 6 days (p<0.05).
CONCLUSION CONCLUSIONS
SMS application appears to be a promising adjuvant therapy for the treatment of neuroblastoma since it decreases the survival of SH-SY5Y neuroblastoma cells.

Identifiants

pubmed: 36974821
pii: 43/4/1427
doi: 10.21873/anticanres.16291
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1427-1436

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Helouise Richardt Medeiros (HR)

Laboratory of Pain Pharmacology and Neuromodulation, Preclinical Studies-Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Post-Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

José Antônio Fagundes Assumpção (JA)

Department of Pharmacology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, U.S.A.

Dirson João Stein (DJ)

Laboratory of Pain Pharmacology and Neuromodulation, Preclinical Studies-Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Post-Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Eduardo Cremonese Filippi-Chiela (EC)

Department of Morphological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Center of Biotechnology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Felipe Fregni (F)

Laboratory of Neuromodulation, Department of Physical Medicine & Rehabilitation, Spaulding Rehabilitation Hospital & Massachusetts General Hospital, Harvard Medical School and Center for Non-invasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, U.S.A.

Wolnei Caumo (W)

Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Paulo Roberto Stefani Sanches (PR)

Research and Development Service in Biomedical Engineering-Research and Graduate Group of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Iraci L S Torres (ILS)

Laboratory of Pain Pharmacology and Neuromodulation, Preclinical Studies-Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; iltorres@hcpa.edu.br.
Post-Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH